Skip to main content
Journal cover image

Management of Pulmonary Arterial Hypertension in the Pediatric Patient.

Publication ,  Journal Article
Ezekian, JE; Hill, KD
Published in: Curr Cardiol Rep
November 28, 2019

PURPOSE OF REVIEW: Pediatric pulmonary arterial hypertension (PAH) is associated with significant morbidity and mortality. Herein we review the diagnosis and classification for pediatric PAH and detail the current therapeutic options available for use in the pediatric PAH population. RECENT FINDINGS: Classification and treatment of pediatric PAH is guided by adult criteria and treatment algorithms, yet the distribution of factors contributing to PAH in children differs significantly from that seen in adults. It is necessary to understand these differences in order to appropriately tailor therapy to the needs of the child or adolescent. An expanding array of targeted PAH drugs are now approved for use in adults, and many of these drugs are used "off-label" to treat children and adolescents with PAH. Use of these novel therapies has coincided with marked improvement in outcomes, suggesting significant benefit. However, because most of these drugs have not been studied in rigorous randomized, controlled trials in children, it is critical that physicians understand their mechanisms of action, potential benefits, and safety profiles. Pediatric PAH outcomes have improved substantially in the modern era, coinciding with the "off-label" use of targeted PAH drugs in children and adolescents. Ideally, care should be provided at centers with specialized expertise in the diagnosis and treatment of pediatric PAH by providers who understand the appropriate diagnostic algorithms, classification schemes, and treatment approaches.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Cardiol Rep

DOI

EISSN

1534-3170

Publication Date

November 28, 2019

Volume

21

Issue

12

Start / End Page

162

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Pulmonary Arterial Hypertension
  • Prostaglandins I
  • Phosphodiesterase 5 Inhibitors
  • Nitric Oxide
  • Hypertension, Pulmonary
  • Humans
  • Endothelins
  • Endothelin Receptor Antagonists
  • Child
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ezekian, J. E., & Hill, K. D. (2019). Management of Pulmonary Arterial Hypertension in the Pediatric Patient. Curr Cardiol Rep, 21(12), 162. https://doi.org/10.1007/s11886-019-1229-2
Ezekian, Jordan E., and Kevin D. Hill. “Management of Pulmonary Arterial Hypertension in the Pediatric Patient.Curr Cardiol Rep 21, no. 12 (November 28, 2019): 162. https://doi.org/10.1007/s11886-019-1229-2.
Ezekian JE, Hill KD. Management of Pulmonary Arterial Hypertension in the Pediatric Patient. Curr Cardiol Rep. 2019 Nov 28;21(12):162.
Ezekian, Jordan E., and Kevin D. Hill. “Management of Pulmonary Arterial Hypertension in the Pediatric Patient.Curr Cardiol Rep, vol. 21, no. 12, Nov. 2019, p. 162. Pubmed, doi:10.1007/s11886-019-1229-2.
Ezekian JE, Hill KD. Management of Pulmonary Arterial Hypertension in the Pediatric Patient. Curr Cardiol Rep. 2019 Nov 28;21(12):162.
Journal cover image

Published In

Curr Cardiol Rep

DOI

EISSN

1534-3170

Publication Date

November 28, 2019

Volume

21

Issue

12

Start / End Page

162

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Pulmonary Arterial Hypertension
  • Prostaglandins I
  • Phosphodiesterase 5 Inhibitors
  • Nitric Oxide
  • Hypertension, Pulmonary
  • Humans
  • Endothelins
  • Endothelin Receptor Antagonists
  • Child